Radhika Sarda

Radhika Sarda

Auto-generated profile, based on publicly available information

Radhika Sarda

Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Open access
SSShubham Sahni
Shubham Sahni
GGGaurav NOT AVAILABLE Gupta
Gaurav NOT AVAILABLE Gupta
RSRadhika Sarda
Radhika Sarda
SPShivam Pandey
Shivam Pandey
RPR.M. Pandey
R.M. Pandey
SSSanjeev Sinha
Sanjeev Sinha
This meta-analysis aims to highlight the impact of cardio-metabolic comorbidities on COVID-19 severity and mortality. A thorough search on major online databases was done for studies describing the clinical outcomes of COVID-19 patients. We used random-effects model to compute pooled estimates for critical or fatal disease. A total of 20,475 patients from 33 eligible studies were included. Maximum risk of development of critical or fatal COVID-19 disease was seen in patients with underlying cardiovascular disease [OR: 3.44, 95% CI: 2.65–4.48] followed by chronic lung disease, hypertension and diabetes mellitus. Of the total cases, 64% had one of the four comorbidities with the most prevalent being hypertension with a pooled prevalence of 27%. Presence of comorbidities like cardiovascular disease, chronic lung disease, hypertension and diabetes mellitus led to a higher risk of development of critical or fatal COVID-19 disease, with maximum risk seen with underlying cardiovascular disease.

25 November 2020 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
RSR Sarda
R Sarda
SSS Swain
S Swain
ARANIMESH RAY
ANIMESH RAY
NWNaveet Wig
Naveet Wig
India continues to battle the second wave of COVID-19 and has recently reported the highest number of cases ever in a single day from a country. As severe COVID-19 continues to claim thousands of lives in this country, there has also been a recent spate of COVID-19-associated mucormycosis (CAM) cases which have garnered attention globally. More than 14 000 cases of CAM have been reported from all over India with many states resorting to declaration of an epidemic as well as making it a notifiable disease. 1 We wish to elaborate on the evolving situation of CAM in India with special attention to the association of mucormycosis with COVID-19, the pathophysiological basis for CAM, likely reasons for preponderance of CAM in India as well as the core management issues.

5 August 2022 in Journal of Patient Experience
Verified
Journal Article
Open access
RSRadhika Sarda
Radhika Sarda
AKArvind Kumar
Arvind Kumar
ACAnkit Chandra
Ankit Chandra
MBMegha Bir
Megha Bir
SKSanchit Kumar
Sanchit Kumar
NWNaveet Wig
Naveet Wig
Literature is lacking on the spectrum of symptoms of long COVID-19 (defined as symptoms persisting beyond 28 days of diagnosis) and its impact on quality of life. This single-center, cross-sectional study included mild COVID-19 cases as determined by a positive real-time reverse transcription polymerase chain reaction test. Patients were contacted at least 28 days after diagnosis and were interviewed telephonically using semi-structured questionnaires for duration of symptoms, fatigue using Fatigue Severity Scale (FSS) and quality of life using the World Health Organization Quality of Life: Brief Version (WHOQOL-BREF). A total of 251 COVID-19 patients were included; of which 169 (67.3%) were males. The mean age of the patients was 35.8 years (SD = 12.5). The prevalence of long COVID-19 was 28.2% (n = 71, 95% CI: 23.0–34.2). The most common symptoms involved the musculoskeletal system (12.7%), upper respiratory tract (7.6%), and fatigue among 17 (6.8%) patients. Patients with long COVID-19 had significantly higher FSS score and lower WHOQOL-BREF score compared to the patients without long COVID-19 (<28 days).

27 August 2021 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
PDF file
ACAnkit Chandra
Ankit Chandra
RSRadhika Sarda
Radhika Sarda
AKArvind Kumar
Arvind Kumar
MBMegha Bir
Megha Bir
PPPragyan Paramita Parija
Pragyan Paramita Parija
NWNaveet Wig
Naveet Wig
Background: Currently, there is no data on the impact of COVID-19 on patients' income and work in India. Methods: We conducted a cross-sectional study at a tertiary hospital in New Delhi. We included all the patients who were ≥18 years of age and consecutively diagnosed with COVID-19 between the 1st of May 2020 to 31st July 2020. Patients were interviewed by a physician using a semi-structure questionnaire. Data were collected on socio-economic status, occupation, income loss, leaves taken, decrease in work efficiency (self-perceived) and about-facing any stigma/discrimination at the workplace. Results: Out of 245 patients, 190 patients were employed. A total of 126 patients (66.3%) self-reported their work was affected due to COVID-19 disease. A total of 30.5% of patients (n = 58/190) reported deduction in their salary. The median amount of salary loss was INR 10,000 (IQR 9000–25000). Decrease in income and work efficiency (self-perceived) was found to be 37.3% (n = 71) and 12.1% (n = 23), respectively. A total of 47 patients (37.3%) took personal leaves (median number – 17 days (IQR 14–25), and discrimination/stigma related to the COVID-19 at the workplace was faced by 22.6% of patients. Conclusion: Income and work of a substantial number of patients was affected due to COVID-19, as there was a decrease in income and work efficiency. Patients also had to take personal leaves and face stigma in the workplace. This will inform the policymakers to formulate strategies to mitigate the impact of COVID-19.

15 July 2021 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
RSR Sarda
R Sarda
SSS Swain
S Swain
ARANIMESH RAY
ANIMESH RAY
NWN Wig
N Wig
We thank Sakthivel et al. for their useful comments on our letter on COVID-19-associated Mucormycosis (CAM). Our article, as noted by them, provides an overview of the plausible pathophysiological mechanisms and likely preponderance of CAM in India. 1

1 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SNShivdas Naik
Shivdas Naik
MSManish Soneja
Manish Soneja
SHSoumendra Haldar
Soumendra Haldar
NMNetto George Mundadan
Netto George Mundadan
PGPrerna Garg
Prerna Garg
NWNaveet Wig
Naveet Wig
Background Long COVID, or post-COVID-19 sequelae, is being seen in a growing number of patients reporting a constellation of symptoms, both pulmonary and extrapulmonary. Studies on COVID-19 recovered patients are scarce. Thus, there is a need to add granularity to our existing knowledge about the course and long-term effects of the infection. Aim To describe the clinical details and risk factors of post-COVID sequelae in the North Indian population. Method This prospective observational study was conducted at a tertiary healthcare centre in Northern India between October 2020 to February 2021. Patients aged >18 years with a confirmed COVID-19 disease were recruited after at least two weeks of diagnosis and interviewed for any post-COVID-19 symptoms. Results Of 1234 patients recruited, who were followed up for a median duration of 91 days (IQR: 45-181 days), 495 (40.11%) patients had symptoms. In 223 (18.1%) patients, the symptoms resolved within four weeks, 150 (12.1%) patients had symptoms till twelve weeks, and 122 (9.9%) patients had symptoms beyond twelve weeks of diagnosis of COVID-19. Most common long COVID-19 symptoms included myalgia (10.9%), fatigue (5.5%), shortness of breath (6.1%), cough (2.1%), disturbed sleep (1.4%), mood disturbances (0.48%) and anxiety (0.6%). The major determinants of developing post-COVID-19 symptoms in the patients were hypothyroidism and the severity of the disease. Conclusion Most often, patients complain of myalgias, fatigue, dyspnoea, cough and disturbed sleep. Patients who are hypothyroid or have recovered from moderate to severe COVID-19 are at higher risk of developing post-COVID sequelae. Therefore, a multidisciplinary approach is required to diagnose and manage COVID-19 recovered patients.